Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lunai Bioworks ( (LNAI) ) has shared an update.
On February 6, 2026, Lunai Bioworks received a notice from Nasdaq stating that its securities are subject to delisting from The Nasdaq Capital Market after the company failed to meet the minimum bid price requirement of $1.00 per share for 30 consecutive business days from December 23, 2025 through February 5, 2026. Because Lunai Bioworks carried out a 1‑for‑10 reverse stock split on September 30, 2025, it is ineligible for the usual 180‑day grace period to regain compliance, intensifying pressure on its listing status.
Unless reversed, Nasdaq’s determination would lead to a trading suspension on February 18, 2026 and subsequent filing to delist and deregister the securities from the exchange, which could materially affect liquidity and investor access to the stock. Lunai Bioworks has requested a hearing before a Nasdaq Hearings Panel, a move that temporarily stays the suspension and delisting process, but there is no assurance the company’s appeal will succeed, leaving stakeholders facing heightened uncertainty.
More about Lunai Bioworks
Lunai Bioworks, Inc. operates in the biotechnology sector, though the specific products, services, or therapeutic focus of the company are not detailed in the disclosure. The company’s securities are listed on The Nasdaq Capital Market, indicating it is publicly traded and subject to U.S. exchange listing standards and regulatory reporting requirements.
Average Trading Volume: 1,155,003
Technical Sentiment Signal: Sell
Current Market Cap: $24.84M
For a thorough assessment of LNAI stock, go to TipRanks’ Stock Analysis page.